Literature DB >> 8423760

Effect of ibuprofen use on muscle soreness, damage, and performance: a preliminary investigation.

S M Hasson1, J C Daniels, J G Divine, B R Niebuhr, S Richmond, P G Stein, J H Williams.   

Abstract

Twenty subjects were randomly assigned to: 1) prophylactic ibuprofen (N = 5) [400 mg TID initiated 4 h before collection of baseline data and strenuous eccentric exercise bout], 2) therapeutic ibuprofen (N = 5) [400 mg TID initiated 24 h after baseline], 3) placebo (N = 5), or 4) control (N = 5). Muscle soreness perception, plasma creatine kinase, knee extensor torque, and EMG of the quadriceps were evaluated at baseline, 24, and 48 h. The prophylactic ibuprofen group had between 40 and 50% less muscle soreness perception and significantly less decline in isometric, concentric, and eccentric torque at 24 h compared with the other three groups (P < 0.05). At 48 h both prophylactic and therapeutic ibuprofen had significantly less muscle soreness perception and decline in torque than the placebo and control groups (P < 0.05). There was no difference between the amount of muscle damage between the four groups at 24 and 48 h. Vastus medialis and lateralis EMG magnitude decreased across time. Vastus lateralis EMG magnitude had significantly less decline from baseline for prophylactic ibuprofen compared with the other three treatments at 24 h, while both prophylactic and therapeutic ibuprofen had significantly less decline at 48 h. These data indicate that a prophylactic dosage of ibuprofen does not prevent CK release from muscle, but does decrease muscle soreness perception and may assist in restoring muscle function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8423760     DOI: 10.1249/00005768-199301000-00003

Source DB:  PubMed          Journal:  Med Sci Sports Exerc        ISSN: 0195-9131            Impact factor:   5.411


  30 in total

Review 1.  Anti-inflammatory treatment of muscular injuries in sport. An update of recent studies.

Authors:  L C Almekinders
Journal:  Sports Med       Date:  1999-12       Impact factor: 11.136

Review 2.  Delayed onset muscle soreness : treatment strategies and performance factors.

Authors:  Karoline Cheung; Patria Hume; Linda Maxwell
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

3.  Rhabdomyolysis/myoglobinemia and NSAID during 48 h ultra-endurance exercise (adventure racing).

Authors:  Emma Wichardt; C Mikael Mattsson; Björn Ekblom; Karin Henriksson-Larsén
Journal:  Eur J Appl Physiol       Date:  2010-12-23       Impact factor: 3.078

Review 4.  The mechanisms of massage and effects on performance, muscle recovery and injury prevention.

Authors:  Pornratshanee Weerapong; Patria A Hume; Gregory S Kolt
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

5.  Efficacy of a tart cherry juice blend in preventing the symptoms of muscle damage.

Authors:  D A J Connolly; M P McHugh; O I Padilla-Zakour; L Carlson; S P Sayers
Journal:  Br J Sports Med       Date:  2006-06-21       Impact factor: 13.800

6.  Effect of whirlpool therapy on the signs and symptoms of delayed-onset muscle soreness.

Authors:  L A Kuligowski; S M Lephart; F P Giannantonio; R O Blanc
Journal:  J Athl Train       Date:  1998-07       Impact factor: 2.860

7.  Pathophysiology of acute exercise-induced muscular injury: clinical implications.

Authors:  P Page
Journal:  J Athl Train       Date:  1995-03       Impact factor: 2.860

8.  The effects of high-volt pulsed current electrical stimulation on delayed-onset muscle soreness.

Authors:  D L Butterfield; D O Draper; M D Ricard; J W Myrer; S S Schulthies; E Durrant
Journal:  J Athl Train       Date:  1997-01       Impact factor: 2.860

Review 9.  The prevention and treatment of exercise-induced muscle damage.

Authors:  Glyn Howatson; Ken A van Someren
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

10.  Does post-exercise massage treatment reduce delayed onset muscle soreness? A systematic review.

Authors:  E Ernst
Journal:  Br J Sports Med       Date:  1998-09       Impact factor: 13.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.